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Summary
The Crohn’s-disease-susceptibility protein, NOD2, coordi-
nates signaling responses upon intracellular exposure to
bacteria [1–6]. Although NOD2 is known to activate NFkB, lit-
tle is known about the molecular mechanisms by which
NOD2 coordinates functionally separate signaling pathways
such as NFkB, JNK, and p38 to regulate cytokine responses
[3–6]. Given that one of the characteristics of Crohn’s dis-
ease is an altered cytokine response to normal bacterial flora
[1, 2], the coupling of signaling pathways could be important
for Crohn’s-disease pathophysiology.We find that aMAP3K,
MEKK4, binds to RIP2 to sequester RIP2 from the NOD2 sig-
naling pathway. This MEKK4:RIP2 complex dissociates
upon exposure to the NOD2 agonist, MDP, allowing NOD2
to bind to RIP2 and activate NFkB. MEKK4 thus sequesters
RIP2 to inhibit the NOD2:RIP2 complex from activating
NFkB signaling pathways, and Crohn’s-disease-associated
NOD2 polymorphisms cannot compete with MEKK4 for
RIP2 binding. Lastly, we find thatMEKK4 helps dictate signal
specificity downstream of NOD2 activation as knockdown of
MEKK4 in macrophages exposed to MDP causes increased
NFkB activity, absent p38 activity, and hyporesponsiveness
to TLR2 and TLR4 agonists. These biochemical findings
suggest that basal inhibition of the NOD2-driven NFkB path-
way by MEKK4 could be important in the pathogenesis of
Crohn’s disease.
Results
MEKK4 Binds to and Sequesters RIP2
MAP3K7 (TAK1) binds to RIP2 and is responsible for NFkB ac-
tivation downstream of the NOD2:RIP2 complex [7–9], sug-
gesting that the MAP3Ks help coordinate NOD2 signaling.
For this reason, we screened a number of other MAP3Ks for
binding to RIP2. As an example of the screening strategy,
HEK293 cells were transfected with Omni-tagged RIP2 and
HA-tagged MEKK2, MEKK3, or MEKK4. The MAP3Ks were im-
munoprecipitated, and the binding of the immunoprecipitated
MAP3K to RIP2 was assayed by Western blot (Figure 1A). Of
the MAP3Ks tested, only MEKK4 bound to RIP2 (Figure 1A).
Cotransfection of CFP-tagged RIP2 and YFP-tagged MEKK4,
followed by confocal microscopy, showed that RIP2 and
MEKK4 colocalize within the cell (Figure 1B; individual locali-
zation of both the CFP-tagged RIP2 and the YPF-tagged
MEKK4 are shown in Figure S1, available online). We next
sought to determine whether RIP2 could bind endogenous
MEKK4 and to determine the effect of the NOD2 agonist
*Correspondence: dwa4@case.eduMDP [10, 11] on this interaction. RAW 264.7 cells were treated
with MDP for 0, 30, 60, or 90 min. Lysates were generated and
MEKK4 was immunoprecipitated. Western blotting showed
that in the unstimulated state, MEKK4 bound to RIP2
(Figure 1C). As MDP activates NFkB (as shown by phospho-
IkBa blot, bottom panel Figure 1C), the MEKK4:RIP2 complex
dissociates (Figure 1C), and this was present in reciprocal
coimmunoprecipitations (Figure 1C). Lastly, upon MDP stimu-
lation, there was a fraction of MEKK4 that had slower mobility
on SDS-PAGE. This appears to be a RIP2-dependent post-
translational modification on MEKK4 and will be detailed in
subsequent work.
Because MDP stimulates RIP2’s binding to NOD2, these
findings suggest that the intracellular presence of MDP causes
RIP2 to dissociate from MEKK4 and bind to NOD2 to cause
NFkB activation. For testing this in a more controlled environ-
ment, HEK293 cells were transfected with MEKK4, RIP2, and/
or NOD2 in either the absence (Figures 2A and 2B) or the pres-
ence (Figures 2C and 2D) of MDP, and the binding complexes
were assayed. In the absence of MDP, MEKK4 competed RIP2
from NOD2 (Figures 2A and 2B), whereas in the presence
of MDP, NOD2 was able to compete RIP2 from MEKK4 (Fig-
ures 2C and 2D, Figure S2B). MDP exposure in the absence
of NOD2 had no effect on the MEKK4:RIP2 complex
(Figure S2A). These data imply that cellular MDP exposure im-
proves the binding of NOD2 to RIP2 such that RIP2 dissociates
from MEKK4. Next, for determination of whether MEKK4 and
NOD2 competed for the same region of RIP2, a deletion mu-
tant of RIP2 that lacked the CARD domain was generated.
This deletion mutant retained the ability to bind MEKK4
(Figure S3B) but lost the ability to bind to NOD2 (Figure S3C),
suggesting that separate regions of RIP2 were responsible
for binding MEKK4 and NOD2. Lastly, for determination of
whether two different classes of Crohn’s-disease-associated
NOD2 polymorphisms were able to compete RIP2 from
MEKK4 in the presence of MDP, cotransfection experiments
were performed with the use of either the loss-of-function
L1007insC NOD2 allele or the dominant negative, ulcerative-
colitis-like Crohn’s-disease NOD2 mutant (D291N). Wild-type
(WT) NOD2, L1007insC, and D291N could not compete
with MEKK4 in the absence of MDP (Figure 2E). Although
WT NOD2 could compete with MEKK4 for RIP2 binding in
the presence of MDP, L1007insC and D291N NOD2 could
not compete with MEKK4 for RIP2 binding when MDP was
present (Figure 2F), consistent with these susceptibility
proteins’ inability to fully activate NFkB after MDP stimulation
[3, 5, 6].
MEKK4’s Sequestration of RIP2 Inhibits NOD2-Induced
NFkB Signaling
These findings imply that MEKK4 may sequester RIP2 to in-
hibit NOD2-directed signaling. For determining the functional-
ity of the MEKK4:RIP2 interaction, the kinase-dead versions of
the MAP3Ks were assayed for their ability to inhibit RIP2-
induced NEMO ubiquitination. Because the NOD2:RIP2
complex strongly stimulates the K63-linked polyubiquitination
of the IKK scaffolding protein NEMO, polyubiquitination of
NEMO can assay for RIP2’s activation of the NFkB signaling
Figure 1. MEKK4 Binds to Endogenous RIP2, and NOD2 Activation Causes Dissociation of the RIP2:MEKK4 Complex
(A) In a screening strategy designed to identify the MAP3Ks that bind to RIP2, HA-tagged MEKK2, MEKK3, and MEKK4 were cotransfected into 293 cells with
Omni-tagged RIP2. After immunoprecipitation, Western blotting was performed with the indicated antibodies.
(B) For determining whether RIP2 and MEKK4 colocalized in the cell, CFP-RIP2 and YFP-MEKK4 fusion constructs were generated. 293 cells were trans-
fected, and confocal microscopy was performed. In the basal, unstimulated state, RIP2 and MEKK4 colocalized. Multiple views with merging of the images
are shown.
(C) For determining whether endogenous RIP2 and MEKK4 bound one another and whether this complex persists in response to NOD2 activation (via MDP
exposure), RAW 264.7 cells were stimulated with 20 mg/mL MDP for 0, 30, 60, or 90 minutes. Cells were lysed and subjected to immunoprecipitation with
anti-MEKK4 or anti-RIP2. Western blotting was performed after extensive washing of the immunoprecipitate. As a control for MDP activation, lysates were
Western blotted with anti-phospho-IkBa and anti-total IkBa. Endogenous MEKK4 binds to endogenous RIP2 in the unstimulated state. As the NFkB pathway
is activated (shown by the anti-phospho-IkBa blot), MEKK4’s binding to RIP2 greatly decreases. This pattern is seen in reciprocal coimmunoprecipitations.
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tagged ubiquitin and myc-tagged K399R NEMO. The K399R
NEMO mutant was utilized, because this decreases basal
NEMO ubiquitination and more readily assays for the ubiquiti-
nation site induced by RIP2 (K285) [13]. These ubiquitination
experiments were performed under high-stringency condi-
tions (0.25% SDS, 1 M NaCl) for reducing the possibility of
artifactually assaying ubiquitinated NEMO binding proteins.
Of the MAP3Ks tested, only MEKK4 and TAK1 were able to in-
hibit RIP2-induced NEMO ubiquitination, and kinase-dead
MEKK4 inhibited this process much better than did kinase-
dead TAK1 (Figure 3A). For determining whether this effect
was dependent on the kinase activity of MEKK4, WT MEKK4
was used in a similar experiment. WT MEKK4 inhibited RIP2-
induced NEMO ubiquitination to the same extent as did
kinase-dead MEKK4 (Figure 3B). Thus, consistent with thesequestration model, the kinase activity of MEKK4 is not
required for inhibition of RIP2-induced NEMO ubiquitination.
Because MEKK4 strongly inhibited NEMO ubiquitination,
MEKK4 binding to RIP2 could be a mechanism for inhibiting
basal NOD2:RIP2-induced NFkB activity. For testing this and
determining the effect of MEKK4 on other NOD2:RIP2-stimu-
lated pathways [14–18], cells were transfected with GST-
IKKb (Figure 3C), IkBa (Figure 3D), FLAG-JNK (Figure 3E), or
FLAG-p38 (Figure 3F) in the presence or absence of MEKK4
or RIP2. Activation of these proteins was assayed by Western
blot with phospho-specific antibodies. MEKK4’s inhibitory ef-
fect was specific for the NFkB pathway, because expression of
MEKK4 strongly inhibited both RIP2-induced IKK activation
and RIP2-induced IkBa phosphoryation (Figures 3C and 3D).
MEKK4 did not affect RIP2’s activation of JNK (Figure 3E),
and RIP2 overexpression did not affect MEKK4’s activation
of p38 (Figure 3F). These findings imply that by allowing JNK or
p38 activation while inhibiting NFkB, MEKK4 may be an impor-
tant regulatory point for the coordination of signaling path-
ways activated downstream of MDP.
Knockdown of MEKK4 Causes Increased NFkB Signaling
For overcoming the limitations of an overexpression system
and further establishing the physiological relevance of the
sequestration model, MEKK4 expression was inhibited by
Figure 2. NOD2 Competes with MEKK4 for RIP2 Binding Only when the Cell Is Stimulated with the NOD2 Agonist, MDP
(A and B) For determining whether NOD2 competes with MEKK4 for RIP2 binding in the unstimulated state, 293 cells were transfected with Omni-tagged
NOD2 and/or HA-tagged MEKK4 or HA-tagged RIP2. NOD2 (A) or MEKK4 (B) were immunoprecipitated, and Western blotting was performed with the
indicated antibodies. RIP2 bound NOD2 only when MEKK4 was absent from the experiment.
(C and D) A similar experiment was performed, with the exception that in this set of experiments, MDP (10 mg/mL) was transfected into the cell for stimulation
of NOD2. After MDP exposure, NOD2 (C) or MEKK4 (D) was immunoprecipitated, and Western blotting was performed with the indicated antibodies. In the
presence of MDP, NOD2 preferentially bound to RIP2 and could compete with MEKK4 for RIP2 binding.
(E and F) For determining whether two disease-specific Crohn’s-disease-associated NOD2 alleles could compete with MEKK4 for binding to RIP2 in the
absence or presence of MDP, two Crohn’s-disease-associated NOD2 alleles (L1007insC and D291N) were transfected with MDP (10 mg/mL) and/or HA-
tagged RIP2 and MEKK4 as indicated. The L1007insC is the mouse homolog, and instead of causing a truncation mutation, it causes a nonsense mutation
leading to a 41-nucleotide elongation before truncation (see [13]). MEKK4 was immunoprecipitated, and Western blotting was performed with the indicated
antibodies. Unlike WT NOD2, neither L1007insC NOD2 nor D291N NOD2 could compete with MEKK4 for binding of RIP2 in the presence or absence of MDP.
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lentiviral shRNA. RAW 264.7 cells were transduced with sepa-
rate lentiviruses targeting different regions of MEKK4 mRNA.
After puromycin selection, clones of each lentivirally trans-
duced population (> 1000) were pooled and assayed for
MEKK4 knockdown. Two cell lines (shRNA#3 and shRNA#4)
showed decreased MEKK4 expression, compared to vector-
only cells (Figure 4A). Clones shRNA#3 and shRNA#4 were
treated with MDP for 0, 30, 60, or 90 minutes. Lysates were
generated, and half the lysates were subjected to immunopre-
cipitation with an anti-NEMO antibody under high-stringency
conditions (0.25% SDS, 1 M NaCl). Western blotting showed
weakly inducible NEMO ubiquitination in the vector-only cell
lines; however, when MEKK4 expression was inhibited
(shRNA#3 and shRNA#4), not only was the basal NEMO ubiq-
uitination (time 0) increased, but the inducible NEMO ubiquiti-
nation was also increased (Figure 4A). This effect mirrored
NFkB activity because, as shown in the phospho-Ikba blot,
cell lines shRNA#3 and shRNA#4 show both increased basal
phospho-IkBa and increased inducible phospho-IkBa when
compared to vector-only cells (Figure 4A). Interestingly, total
IkBa was increased in both MEKK4-knockdown cell lines. Be-
cause IkBa is transcriptionally regulated by NFkB [19], this
could also indicate an increased basal NFkB activity in these
cell lines. JNK activation showed relatively similar activation
kinetics between vector-only cells and MEKK4-knockdown
cells; however, p38 activation was undetectable in the
MEKK4-knockdown cells (Figure 4A). For then determining
the effect of this altered cellular signaling on cytokine produc-
tion in the MEKK4-knockdown cells, basal production levels of
a variety of cytokines were measured. IL-6, IL-10, IL-12, TNFa,
and G-CSF levels were all significantly increased in the unsti-
mulated MEKK4-knockdown macrophages (Figure 4B). Lastly,
expression of MDP-inducible genes was then assayed. Both
RIP2 and A20 were significantly increased both in the basal
state and upon MDP induction in the MEKK4-knockdown mac-
rophages, whereas another innate immune mediator, IRAK4,
which is not inducible by MDP, was unaltered in the MEKK4-
knockdown cells (Figure 4C). These results suggest that the
MEKK4-knockdown cells may show increased basal activa-
tion of the NOD2 pathway. Because recent data suggest that
chronic MDP stimulation causes hyporesponsiveness to Toll-
like Receptor (TLR) agonists [20, 21], the response of the
MEKK4-knockdown cells to TLR2 and TLR4 agonists was
then assayed. Unlike MDP, these cells were hyporesponsive
to both Pam3Cys4 (TLR2 agonist) and LPS (TLR4 agonist) (Fig-
ures S4A and S4B). In addition, synergy between MDP and
these agonists was lost (Figure S4B). Lastly, these cells
showed an inability to fully respond to M. Tuberculosis infec-
tion (Figure S5), an infection in which both TLR2 and NOD2
agonists are present [22]. In sum, these findings support
the model that MEKK4 acts to limit NOD2:RIP2-induced
NFkB activation and specifies innate immunological signal-
transduction mechanisms.
Discussion
In this work, we have identified a mechanism by which basal
activity of the NOD2:RIP2 complex and signal-transduction
specificity downstream of this complex can be controlled.
We identified the MAP3K, MEKK4, as a binding partner of
RIP2 (Figure 1) and showed that MEKK4 could inhibit RIP2-
induced NEMO ubiquitination and IKK activation (Figure 3).
This inhibition was specific to the NFkB pathway, given that
RIP2-induced JNK activation was unaffected by MEKK4
NOD2:RIP2 Signal-Transduction Specificity
1405expression (Figures 3 and 4). We showed biochemically that
endogenous RIP2 binds to MEKK4. Upon exposure to the
NOD2 agonist, MDP, RIP2 dissociates from MEKK4 and binds
to NOD2, such that NFkB activation can be achieved (Figures
1–3). Crohn’s-disease-associated polymorphisms of NOD2
cannot compete with MEKK4 for RIP2 binding (Figure 2F),
and inhibition of MEKK4 expression causes increased MDP-in-
duced NEMO ubiquitination, increased MDP-induced NFkB
activation, and increased basal cytokine production (Figure 4).
This work has implications both for gastrointestinal mucosal
immunology and for the molecular pathophysiology of Crohn’s
disease. NFkB’s role in gastrointestinal inflammation has been
confusing. Many Crohn’s disease patients show too much
NFkB activation, and agents aimed at disrupting TNF-driven
NFkB activity can be efficacious in treating some of these pa-
tients [1, 3]. However, recent mouse work suggests that phys-
iologic NFkB activity may be protective against chronic GI
inflammation, helping to blunt the immune response under
normal circumstances of no inflammation [23]. Likewise, the
role of NFkB in NOD2-driven Crohn’s disease has been confus-
ing. The Crohn’s-disease-susceptibility gene, CARD15, shows
autosomal-recessive genetics, with the Crohn’s-disease-asso-
ciated NOD2 polymorphisms showing loss of function at NFkB
[3, 5, 6]. Anti-TNF agents are no more efficacious in NOD2-
driven Crohn’s disease [24], and NOD2-knockout mice show
no increased intestinal inflammation unless they are manipu-
lated [15, 25]. In contrast, a knockin mouse containing the
most common loss-of-function Crohn’s-disease-associated
NOD2 allele shows the opposite result, that of increased intes-
tinal inflammation [26]. These disparate findings could be
explained in part by the fact that, rather than simply driving
a cytokine response to a pathogenic intracellular bacteria,
NOD2 helps to coordinate cytokine release between various
signaling pathways and by the fact that NOD2 helps to establish
protective, physiologic NFkB activity. These two explanations
may help explain why Crohn’s-disease-associated NOD2
polymorphisms predispose one to the development of Crohn’s
disease. The Crohn’s-disease-associated NOD2 polymor-
phisms may not properly couple signaling pathways to coordi-
nate cytokine release under inflammatory conditions, whereas
under noninflamed conditions, they do not allow protective
physiologic NFkB activation. This manuscript supports this
hypothesis and suggests that the level of control of this
process lies at the MAP3Ks.
This work suggests that the MAP3Ks (specifically TAK1 [7–9]
and MEKK4) coordinate disparate NOD2:RIP2-induced NFkB
and p38 activation. This possibility is concordant with the
MEKK4-knockout mouse. Although efforts to characterize
this mouse are complicated by perinatal lethality due to failure
of neural-tube closure, signaling characterization of both
MEKK42/2 MEFs [27, 28] and MEKK42/2 T cells [29] shows
defective p38 activation, similar to the effects we obtained
in MEKK4-knockdown macrophages. In our hands, MEKK4
knockdown also gave an MDP response similar to that seen
in CARD92/2 cells (lack of p38 signaling, with intact NFkB
signaling [30]), and it will be important that future studies de-
termine whether MEKK4 and CARD9 interact in a signaling
pathway to help coordinate NOD2 signaling responses in
Crohn’s disease.
Conclusions
Because the lumen of the GI tract contains both probiotic and
potentially pathogenic organisms, the normal mucosal surface
Figure 3. MEKK4 Expression Inhibits RIP2-Induced NEMO Ubiquitination and RIP2-Induced IKK Activation
(A) For determining the effect of MEKK4 on RIP2-induced NEMO ubiquitination and determining the MAP3K specificity of this effect, kinase-dead (denoted
as KA—catalytic lysine converted to alanine in each kinase) variants of MEKKs 1, 3, and 4 were transfected into 293 cells with myc-tagged K399R NEMO,
RIP2, and HA-tagged ubiquitin. As a positive control for inhibition of NEMO ubiquitination, kinase-dead TAK1 was utilized. After immunoprecipitation of
NEMO under stringent washing conditions, Western blotting was performed with the indicated antibodies. Kinase-dead MEKK4 specifically and strongly
inhibited RIP2-induced NEMO ubiquitination.
(B) For determining whether the inhibitory effect of MEKK4 on RIP2-induced NEMO ubiquitination was dependent on the kinase activity of MEKK4, WT
MEKK4 or kinase-dead MEKK4 was transfected into 293 cells with myc-tagged K399R NEMO and RIP2 and HA-tagged ubiquitin. After immunoprecipitation,
Western blotting was performed. WT MEKK4 inhibited RIP2-induced NEMO ubiquitination with efficacy similar to that of kinase-dead MEKK4.
(C) Mammalian GST-tagged IKKb was transfected into 293 cells with RIP2 and/or MEKK4. After purification with glutathione-sepharose beads, Western
blots were performed. MEKK4 strongly inhibits RIP2-induced IKKb activation.
(D) 293 cells were transfected with IkBa, RIP2, and/or WT MEKK4 or kinase-dead (KA) MEKK4. Lysates were generated and Western blotting was performed.
RIP2 strongly induces IkBa phosphorylation, and both WT and kinase-dead (KA) MEKK4 inhibit this activation with similar efficacy.
(E) Flag-tagged JNK was transfected into 293 cells with RIP2 and/or MEKK4. After immunoprecipitation with the Flag antibody, Western blots were
performed with the indicated antibodies. RIP2 strongly activates JNK, and MEKK4 expression has no effect on this activation.
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Figure 4. Decreased Expression of MEKK4 Causes Increased MDP-Induced NEMO Ubiquitination, Increased MDP-Induced NFkB Activation, Decreased
MDP-Induced p38 Activation, and Increased Basal Cytokine Production
(A) RAW 264.7 cells were transduced with individual lentiviruses targeting MEKK4. As a control, an empty lentivirus was used. Western blotting was
performed for determining the degree of inhibition of MEKK4 expression. Cell lines MEKK4 shRNA #3 and MEKK4 shRNA #4 showed the greatest loss
of expression and were used for subsequent experiments. These cell lines were then exposed to MDP for 0, 30, 60, or 90 minutes. Lysates were generated,
and half the lysates were subjected to immunoprecipitation under stringent washing conditions (0.25% SDS, 1 M NaCl). Western blots showed that NEMO
ubiquitination was increased basally and was greatly increased under stimulation in the shRNA#3 and shRNA#4 cell lines but not in the vector-only cell line.
In agreement with this finding, phospho-IkBawas increased in these cell lines (both basally and with stimulation), indicating higher NFkB activity. In contrast,
whereas JNK signaling was similar between the vector-only cell line and the shRNA#3 and the shRNA#4 cell lines, p38 signaling was greatly decreased when
MEKK4 expression was inhibited.
(B) For determining whether this increased basal NFkB activation resulted in altered cytokine production, cytokine levels were assayed from these cell lines
by ELISA. IL-6, IL-10, IL-12, TNFa, and G-CSF were all significantly basally upregulated in both MEKK4-knockdown lines. Student’s t test showed that IL-6,
IL-10, TNF, and G-CSF increases had a significance of p < 0.05 (indicated by an asterisk). Given that these cytokines are all regulated by NFkB, these findings
suggest a functional role for the increased NFkB signaling seen in Figure 4A. Error bars are SEM (standard error of the mean) based on triplicate experiments.
(C) Expression of two NFkB-regulated proteins was then assayed either under basal conditions or after overnight MDP stimulation. Both RIP2 and A20 were
significantly upregulated in the MEKK4-knockdown lines. In contrast, the innate immunity protein, IRAK4, whose expression is not regulated by NFkB
activity, was essentially unchanged.
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mechanisms in place for dampening of proinflammatory
NFkB responses, and our work suggests that by sequestering
RIP2, MEKK4 plays a key role in dampening basal NFkB activ-
ity. However, upon pathogen exposure, NFkB activation must
be rapid and the signal transduction mechanisms precise in
order to establish proper cytokine release for eradication of
the offending organism. Given the molecular genetics of both
NOD2 polymorphic patients and various NOD2-deficient
mice, NOD2 may play a central role in both the basal NFkB
response to nonpathogenic bacterial flora and the NFkB(F) Flag-tagged p38 was transfected into 293 cells with RIP2 and/or MEKK
performed. MEKK4 strongly activates p38. RIP2 coexpression has little effectresponse and cytokine-coordination response to pathogenic
bacteria. Our work suggests that MEKK4 helps control both
of these NOD2-driven responses and begins to serve as
a framework by which to study NOD2-driven signaling-
pathway crosstalk.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures and
can be found with this article online at http://www.current-biology.com/
cgi/content/full/18/18/1402/DC1/.4. After immunoprecipitation with the Flag antibody, Western blots were
on this activation.
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